Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Business Wire
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership team, Mr. Hoitt will be responsible for overseeing the Company’s global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome."Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines and accelerating
Show less
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Thomas Leggett as Chief Financial OfficerBusiness Wire
- Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
STOK
Earnings
- 3/25/24 - Beat
STOK
Sec Filings
- 4/29/24 - Form 8-K
- 4/23/24 - Form ARS
- 4/23/24 - Form DEFA14A
- STOK's page on the SEC website